Breakthrough T1D 2026 Government Day – Powering Progress
From March 15–18, more than 200 passionate, motivated Breakthrough T1D Advocates from all 50 states convened in Washington, D.C., for Breakthrough T1D 2026 Government Day. Government Day remains one of Breakthrough T1D’s most impactful ways to effect change. By bringing the lived type 1 diabetes (T1D) experience directly to policymakers, we are accelerating progress toward […]
Deceased Donor Islet Cell Transplantation 101
Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]
Changing the Course of Type 1 Diabetes
Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.
Congress passes bipartisan extension of the Special Diabetes Program, securing critical T1D research funding
Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law, ensuring continued momentum toward better treatments, disease-modifying therapies, and cures. This legislation: These are huge wins for the T1D community […]
Civica’s affordable long-acting insulin now available!
Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]
2025 Top T1D advances: Full speed ahead
How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]
See our advocates. See T1D.
Through grassroots support, Breakthrough T1D advocates help advance treatments, influence policy, and improve global access to care.
Demystifying the pipeline of T1D therapies and devices: Turning ideas into reality
What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]
Tzield receives voucher for expedited review in stage 3 T1D
This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]
Civica long-acting insulin available on January 1, 2026
Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 pens, no more than $55 – for anyone While we […]
